Get started
Author

Sandip Acharya

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase
2018 · François-Xavier Mahon, Carla Boquimpani, et al. · Annals of Internal Medicine · 134
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
2017 · T P Hughes, B Leber, et al. · Leukemia · 44
PDF
Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER)
2022 · Philippe Gevaert, Claus Bachert, et al. · Journal of Allergy and Clinical Immunology · 23
Nilotinib dose‐optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENEST xtnd
2017 · Timothy P. Hughes, Eduardo Munhoz, et al. · British Journal of Haematology · 23
PDF
Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop
2016 · Timothy P. Hughes, Carla Maria Boquimpani, et al. · Blood · 21
Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study.
2016 · Timothy P Hughes, Carla Boquimpani, et al. · Journal of Clinical Oncology · 13
Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase
2016 · François-Xavier Mahon, Carla Maria Boquimpani, et al. · Blood · 11
ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).
2019 · Timothy P. Hughes, Carla Boquimpani, et al. · Journal of Clinical Oncology · 9
Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up
2013 · Brian Leber, Francisco Cervantes, et al. · Blood · 8
Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.
2018 · François-Xavier Mahon, Carla Boquimpani, et al. · Journal of Clinical Oncology · 7
OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided RAS / BRAF wild-type metastatic colorectal cancer.
2025 · Dirk Arnold, Andres Cervantes, et al. · Journal of Clinical Oncology · 4
ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib
2018 · Timothy P. Hughes, Carla Boquimpani, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)
2015 · Timothy P. Hughes, Francisco Cervantes, et al. · Blood · 3
Aliskiren-based stepped-care treatment algorithm provides effective blood pressure control
2011 · D. Richter, C. Mickel, et al. · International Journal of Clinical Practice · 3
PDF
Aliskiren-based Treatment Controls Blood Pressure Independent of Baseline Plasma Renin Activity: 9a.03
2010 · D Richter, C Mickel, et al. · Journal of Hypertension · 3
Diagnostic Accuracy of an Offline CNN Framework Utilizing Multi-View Chest X-Rays for Screening 14 Co-Occurring Communicable and Non-Communicable Diseases
2025 · Latika Giri, Pradeep Raj Regmi, et al. · Diagnostics · 2
PDF
ENESTfreedom and ENESTop Update: Durable Treatment-Free Remission (TFR) at 96 Weeks after Nilotinib Treatment Cessation in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
2017 · Jerald Radich, François-Xavier Mahon, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study
2025 · Rachel E. Sanborn, Caicun Zhou, et al. · Targeted Oncology · 1
PDF
Pf411 Enestop 192‐wk Results: Durability and Impact on Quality of Life of Treatment‐free Remission (tfr) Following Second‐line (2l) Nilotinib (nil) in Patients (pts) With Chronic Myeloid Leukemia (cml)
2019 · F.‐X. Mahon, C. Boquimpani, et al. · HemaSphere · 1
Effect of continued imatinib (IM) in pts with detectable BCR-ABL after ≥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr.
2014 · Nelson Spector, Nelma Cristina D. Clementino, et al. · Journal of Clinical Oncology · 1
Abstract CT217: OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided RAS/BRAF wild-type metastatic colorectal cancer
2026 · Dirk Arnold, Andres Cervantes, et al. · Cancer Research
ENESTxtnd: Impact Of Nilotinib Dose Re-Escalation In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
2013 · Jeff H. Lipton, Luis Meillon, et al. · Blood
Prospective, observational registry of branded imatinib (IM) and nilotinib (NIL) exposure in pregnant women: Voluntary post-authorization safety study.
2012 · Matthews Juma, Solveig Ericson, et al. · Journal of Clinical Oncology
Aliskiren-based Antihypertensive Treatment Regimen Provides Effective Blood Pressure Control in Patients With Diabetes
2011 · D. Richter, C. Mickel, et al. · Journal of Hypertension
Aliskiren-based Stepped Care Treatment Regimen Provides Bp Control in 9/10 Patients With Mild to Moderate Hypertension: Pp.16.98
2010 · D Richter, C Mickel, et al. · Journal of Hypertension
Works count: 25
Citation count: 316
H-index: 8
I10-index: 7
Year
Topic
Type